Dr. Robert Nagourney has been internationally recognized as a pioneer in cancer research and personalized cancer treatment for over 20 years.
Among his many accomplishments, as co-investigator on national cooperative trials, Dr. Nagourney is recognized for the introduction of Cisplatin/Gemcitabine doublets in the treatment of advanced ovarian and breast cancers.
He is the founder and medical director of Nagourney Cancer Institute (formerly Rational Therapeutics) and Clinical Professor at the University of California, Irvine School of Medicine. Also, he is a practicing oncologist and triple board certified in Internal Medicine, Medical Oncology and Hematology.
With more than 20 years experience in human tumor primary culture analyses, Dr. Nagourney has AUTHORED more than 100 manuscripts, book chapters and abstracts including publications in the Journal of Clinical Oncology, Gynecologic Oncology,The Journal of the National Cancer Institute. and British Journal of Cancer.
Dr. Nagourney has been featured on radio, local and national television outlets such as CNN, ABC World News Tonight, CNBC, Extra, Hard Copy, Fox 11 Los Angeles, KTLA5 & ABC7 (Los Angeles), WLWT5 & WCPO9 (Cincinatti), 13WHAM (Rochester, NY) and major newspapers such as the Wall Street Journal, Orange County Register, and Cincinatti Enquirer.
He has also been featured internationally such as on Australian TV show Good Medicine, and Univision's Primer Impacto.
In March 2013, his book Outliving Cancer was released by Basic Health Publications. Outliving Cancer is Dr. Nagourney's story of discovery, the biology of cancer and how best to treat it.
He has also served as a journal reviewer and on the editorial boards of several journals including Clinical Cancer Research, British Journal of Cancer, Gynecologic Oncology, Cancer Research and the Journal of Medicinal Food.
Boston University, BA Chemistry
Summa Cum Laude
Phi Beta Kappa with Distinction in Biochemistry
McGill University, Montreal, Canada
University of California Irvine, Long Beach VA Medical Center
Georgetown University Hospital, Washington DC
Scripps Clinical & Research Institute, La Jolla CA
Recipient of the Scripps Institute Young Investigator Award
Learn more about our personalized testing called, functional profiling, which exposes your living cancer cells to chemotherapy drugs, targeted agents and combinations in the laboratory.
Through this testing Dr. Nagourney and his team can help select the most effective and least toxic drug regimen for your cancer.
In 1995, Dr. Robert Nagourney founded Rational Therapeutics which is now Nagourney Cancer Institute - an accomplished cancer and research facility with a fully accredited federal and state licensed laboratory.
We provide personal cancer strategies based on how your cancer cells respond in the laboratory. This eliminates much of the "guess work" prior to your undergoing the potentially toxic side effects of drug regimens that could prove to be of little value against your cancer.
Steve Evans, Chief Operations Officer, oversees the day-to-day operations of the laboratory, including personnel and data analyses.
With more than 25 years of doing cancer research, Steve has co-authored five manuscripts, 34 research abstracts and has presented research findings at the annual meetings of the American Association of Cancer Research and the American Society of Clinical Oncology.
Most types of cancers can be tested by Nagourney Cancer Institute and samples arrive from all over the US and internationally.
Since the test involves living cancer cells, the samples MUST arrive in a very timely manner, within 24-36 hours.
The short video to the right of a Stage 4 Lung Cancer success story filmed by a local television station provides insight into how Dr. Nagourney uses his laboratory to help cancer patients find the most effective treatment for their particular cancer.
Call us at 1-800-542-4357 or email us to find out if we can help you.
Dr. Nagourney and the team here at Nagourney Cancer Institute have also been cost-effectively assisting pharmaceutical and biotechnology firms streamline the research process and more rapidly providing information not available within the current drug development process.
Our EVA-PCD functional platform allows us to analyze the activity of new compounds in multiple disease types at a fraction of the cost of other research avenues, identifying the most responsive diseases and eliminating tumor types with little activity.